{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:50:25Z","timestamp":1791517825534,"version":"4.3.4"},"reference-count":67,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Clinicians may encounter a variety of skin conditions that present with vesiculobullous lesions in their everyday practice. Pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, and paraneoplastic pemphigus represent the spectrum of autoimmune bullous dermatoses of the pemphigus family. The pemphigus family of diseases is characterized by significant morbidity and mortality. Considering the risks associated with a delayed diagnosis or misdiagnosis and the potential for overlap in clinical features and treatment, evaluation for suspected pemphigus disease often requires thorough clinical assessment and laboratory testing. Diagnosis is focused on individual biopsies for histopathology and direct immunofluorescence. Additional laboratory methods used for diagnosis include indirect immunofluorescence and enzyme-linked immunosorbent assay. Recent advancements, including anti-CD20 therapy, have improved the efficacy and reduced the morbidity of pemphigus treatment. This contribution presents updates on the pathophysiology, clinical features, diagnostic work-up, and medical management of pemphigus. Improved strategies for diagnosis and clinical assessment are reviewed, and newer treatment options are discussed.<\/jats:p>","DOI":"10.3390\/medicina57101080","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T21:37:29Z","timestamp":1633901849000},"page":"1080","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["An Updated Review of Pemphigus Diseases"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5898-8440","authenticated-orcid":false,"given":"Ali M.","family":"Malik","sequence":"first","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville, FL 32606, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tupchong","sequence":"additional","affiliation":[{"name":"Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3318-0143","authenticated-orcid":false,"given":"Simo","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhirup","family":"Are","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville, FL 32606, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-0826","authenticated-orcid":false,"given":"Kiran","family":"Motaparthi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, University of Florida, Gainesville, FL 32606, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/archderm.1980.01640330073017","article-title":"Pemphigus in Hartford County, Connecticut, from 1972 to 1977","volume":"116","author":"Simon","year":"1980","journal-title":"Arch. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/1523-1747.ep12612836","article-title":"Comparative Epidemiology of Pemphigus in Tunisia and France: Unusual Incidence of Pemphigus Foliaceus in Young Tunisian Women","volume":"104","author":"Souissi","year":"1995","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000246946","article-title":"Pemphigus in Oxford, UK, and New Delhi, India: A Comparative Study of Disease Characteristics and HLA Antigens","volume":"189","author":"Wilson","year":"1994","journal-title":"Dermatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2340\/00015555-2706","article-title":"Pemphigus Vulgaris and Pemphigus Foliaceus: Differences in Epidemiology and Mortality","volume":"97","author":"Kridin","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1073\/pnas.88.11.5056","article-title":"Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris","volume":"88","author":"Ahmed","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1073\/pnas.87.19.7658","article-title":"Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris","volume":"87","author":"Ahmed","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archderm.1973.01620270029007","article-title":"Increased frequency of HL-A10 in pemphigus vulgaris","volume":"108","author":"Krain","year":"1973","journal-title":"Arch. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0198-8859(97)00182-1","article-title":"Identical MHC markers in non-Jewish Iranian and Ash-kenazi Jewish patients with pemphigus vulgaris: Possible common central Asian ancestral origin","volume":"57","author":"Mobini","year":"1997","journal-title":"Hum. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1046\/j.1365-4362.2001.01247.x","article-title":"The incidence of pemphigus in the southern region of Saudi Arabia","volume":"40","author":"Tallab","year":"2001","journal-title":"Int. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0030-4220(90)90245-N","article-title":"Oral pemphigus vulgaris in a 6-year-old girl","volume":"69","author":"Laskaris","year":"1990","journal-title":"Oral Surg. Oral Med. Oral Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2340\/0001555562491496","article-title":"Pemphigus: An epidemiological study of patients treated in Finnish hospitals between 1969 and 1978","volume":"62","author":"Hietanen","year":"1982","journal-title":"Acta Derm. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1111\/jdv.16467","article-title":"Prevalence and age distribution of pem-phigus and pemphigoid diseases among paediatric patients in Germany","volume":"34","author":"Holtsche","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1172\/JCI115968","article-title":"Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic","volume":"90","author":"Amagai","year":"1992","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjd.12012","article-title":"Is there an emergent need to modify the desmoglein compensation theory in pemphigus on the basis of Dsg ELISA data and alternative pathogenic mechanisms?","volume":"168","author":"Sardana","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1067\/mjd.2003.438","article-title":"Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris","volume":"48","author":"Jamora","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","unstructured":"Aslanova, M., Yarrarapu, S.N.S., and Zito, P.M. (2021). IgA Pemphigus. StatPearls, StatPearls."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaad.2019.11.059","article-title":"IgA Pemphigus: A Systematic Review","volume":"82","author":"Kridin","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/CCID.S100802","article-title":"Paraneoplastic pemphigus: A short review","volume":"9","author":"Czernik","year":"2016","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/jid.2011.249","article-title":"Incidence, Mortality, and Causes of Death of Patients with Pemphigus in Taiwan: A Nationwide Population-Based Study","volume":"132","author":"Huang","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.autrev.2015.06.005","article-title":"Oral mucosal manifestations of autoimmune skin diseases","volume":"14","author":"Mustafa","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_21","first-page":"5056","article-title":"Pemphigus vulgaris\u2014Approach and management (Review)","volume":"18","author":"Popescu","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","article-title":"The adjuvant therapy of pemphigus. An update","volume":"132","author":"Bystryn","year":"1996","journal-title":"Arch. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13023-015-0263-4","article-title":"Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: A retrospective cohort study","volume":"10","author":"Baican","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_24","unstructured":"Messersmith, L., and Krauland, K. (2021). Pemphigus Vegetans. StatPearls, StatPearls Publishing."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.det.2011.03.012","article-title":"Diagnosis and Clinical Features of Pemphigus Foliaceus","volume":"29","author":"James","year":"2011","journal-title":"Dermatol. Clin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1590\/abd1806-4841.20188235","article-title":"Fogo selvagem: Endemic pemphigus foliaceus","volume":"93","author":"Aoki","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1056\/NEJM199012203232503","article-title":"Paraneoplastic Pemphigus","volume":"323","author":"Anhalt","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_29","unstructured":"Pile, H.D., Yarrarapu, S.N.S., and Crane, J.S. (2021). Drug Induced Pemphigus. StatPearls, StatPearls Publishing."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.oraloncology.2003.09.020","article-title":"Neoplasms associated with paraneoplastic pemphigus: A review with emphasis on non-hematologic malignancy and oral mucosal manifestations","volume":"40","author":"Kaplan","year":"2004","journal-title":"Oral Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199905063401805","article-title":"The Mechanism of Respiratory Failure in Paraneoplastic Pemphigus","volume":"340","author":"Nousari","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1365-2133.2003.05659.x","article-title":"Paraneoplastic pemphigus in association with Castleman\u2019s disease","volume":"149","author":"Nikolskaia","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1440-1843.2008.01397.x","article-title":"Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome","volume":"14","author":"Maldonado","year":"2009","journal-title":"Respirology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/bjd.14162","article-title":"Clinical and immunological findings in 104 cases of paraneoplastic pemphigus","volume":"173","author":"Ohzono","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-4632.2009.03995.x","article-title":"Paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome","volume":"48","author":"Sehgal","year":"2009","journal-title":"Int. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1346-8138.2010.01192.x","article-title":"Paraneoplastic pemphigus associated with corneal perforation and cutaneous alternariosis: A case report and review of cases treated with rituximab","volume":"38","author":"Anan","year":"2011","journal-title":"J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/cup.14004","article-title":"Paraneoplastic pemphigus: Revised diagnostic criteria based on literature analysis","volume":"48","author":"Svoboda","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.2004.00280.x","article-title":"Alemtuzumab-induced remission of both severe para-neoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia","volume":"73","author":"Hohwy","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1027-8117(10)60001-8","article-title":"Paraneoplastic pemphigus","volume":"28","author":"Lee","year":"2010","journal-title":"Dermatol. Sin."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Paolino, G., Didona, D., Magliulo, G., Iannella, G., Didona, B., Mercuri, S.R., Moliterni, E., Donati, M., Ciofalo, A., and Granata, G. (2017). Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122532"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archdermatol.2012.1830","article-title":"Prognostic Factors of Paraneoplastic Pemphigus","volume":"148","author":"Leger","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.clindermatol.2011.01.014","article-title":"IgA pemphigus","volume":"29","author":"Tsuruta","year":"2011","journal-title":"Clin. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0190-9622(91)70128-O","article-title":"IgA pemphigus foliaceus with a clinical presentation of pemphigus herpetiformis","volume":"24","author":"Chorzelski","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjd.14408","article-title":"Laboratory diagnosis of pemphigus: Direct immunofluorescence remains the gold standard","volume":"175","author":"Giurdanella","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/CCID.S75908","article-title":"Management of pemphigus vulgaris: Challenges and solutions","volume":"8","author":"Gregoriou","year":"2015","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-Line Rituximab Combined with Short-Term Prednisone Versus Prednisone Alone for the Treatment of Pem-phigus (Ritux 3): A Prospective, Multicentre, Parallel-Group, Open-Label Randomised Trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s12325-016-0343-4","article-title":"Management of Pemphigus Vulgaris","volume":"33","author":"Cholera","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clindermatol.2011.03.017","article-title":"Severity score indexes for blistering diseases","volume":"30","author":"Daniel","year":"2012","journal-title":"Clin. Dermatol."},{"key":"ref_52","first-page":"e2020050","article-title":"Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment","volume":"10","author":"Casanova","year":"2020","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jamadermatol.2014.2421","article-title":"First-line Treatment of Pemphigus Vulgaris with a Combination of Rituximab and High-Potency Topical Corticosteroids","volume":"151","author":"Cosnes","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors Associated with Complete Remission After Rituximab Therapy for Pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamadermatol.2017.5176","article-title":"Rituximab as Single Long-term Maintenance Therapy in Patients with Difficult-to-Treat Pemphigus","volume":"154","author":"Sanchez","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_56","unstructured":"(2018, June 07). Genentech Press Releases. Available online: https:\/\/www.gene.com\/media\/press-releases\/14727\/2018-06-07\/fda-approves-genentechs-rituxan-rituxima."},{"key":"ref_57","unstructured":"(2021, June 24). Rituxan Prices, Coupons & Patient Assistance Programs. Available online: https:\/\/www.drugs.com\/price-guide\/rituxan."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archderm.139.6.739","article-title":"Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus with Mycophenolate Mofetil","volume":"139","author":"Mimouni","year":"2003","journal-title":"Arch. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Esmaili","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_60","first-page":"1285","article-title":"Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris","volume":"27","author":"Mortazavizadeh","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200708020-00004","article-title":"Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris","volume":"8","author":"Olszewska","year":"2007","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_62","first-page":"bcr2013200479","article-title":"Pemphigus vulgaris: A multidisciplinary approach to management","volume":"2013","author":"Vinall","year":"2013","journal-title":"Case Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4103\/ccd.ccd_464_19","article-title":"Current Therapeutic Modalities of Immunobullous Lesions","volume":"10","author":"Sadaksharam","year":"2019","journal-title":"Contemp. Clin. Dent."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2009.11.588","article-title":"Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions","volume":"63","author":"Lehman","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/jamadermatol.2017.2808","article-title":"Determining the Incidence of Pneumocystis Pneumonia in Patients with Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis","volume":"153","author":"Amber","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1684\/ejd.2012.1662","article-title":"Intraepidermal neutrophilic IgA pemphigus successfully treated with dapsone","volume":"22","author":"Hirata","year":"2012","journal-title":"Eur. J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2005.02.051","article-title":"Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil","volume":"53","author":"Howell","year":"2005","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/1080\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:11:06Z","timestamp":1760166666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/1080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":67,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["medicina57101080"],"URL":"https:\/\/doi.org\/10.3390\/medicina57101080","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,9]]}}}